Projects per year
Fingerprint
Dive into the research topics where Richard Geoffrey Vile is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 10 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Core A: Administrative Core
Gores, G. J., Vile, R. G., Leof, E. B., Mandrekar, S. J., Torbenson, M. & Alberts, S. R.
Project: Research project
-
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
Vile, R. G. & Kinney, L.
5/7/14 → 4/30/19
Project: Research project
-
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
Vile, R. G. & Kinney, L.
1/1/09 → 11/30/14
Project: Research project
-
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm
Vile, R. G. & Kinney, L.
7/1/08 → 5/31/14
Project: Research project
-
T Cell Based Carriers for In Vivo Gene Therapy of Cancer
Vile, R. G., Kinney, L. & Kinney, L.
4/1/04 → 11/30/14
Project: Research project
Research output
-
APOBEC and cancer viroimmunotherapy: Thinking the unthinkable
Vile, R. G., Melcher, A., Pandha, H., Harrington, K. J. & Pulido, J. S., Jun 2021, In: Clinical Cancer Research. 27, 12, p. 3280-3290 11 p.Research output: Contribution to journal › Review article › peer-review
-
Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas
Monie, D. D., Correia, C., Zhang, C., Ung, C. Y., Vile, R. G. & Li, H., Dec 2021, In: Scientific reports. 11, 1, 11198.Research output: Contribution to journal › Article › peer-review
Open Access -
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
Annels, N. E., Simpson, G. R., Denyer, M., Arif, M., Coffey, M., Melcher, A., Harrington, K., Vile, R. & Pandha, H., Mar 26 2021, In: Molecular Therapy - Oncolytics. 20, p. 434-446 13 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
Kottke, T., Tonne, J., Evgin, L., Driscoll, C. B., van Vloten, J., Jennings, V. A., Huff, A. L., Zell, B., Thompson, J. M., Wongthida, P., Pulido, J., Schuelke, M. R., Samson, A., Selby, P., Ilett, E., McNiven, M., Roberts, L. R., Borad, M. J., Pandha, H., Harrington, K. & 2 others, , Dec 2021, In: Nature communications. 12, 1, 1930.Research output: Contribution to journal › Article › peer-review
Open Access -
Parking car t cells in tumours: Oncolytic viruses as valets or vandals?
Evgin, L. & Vile, R. G., Mar 1 2021, In: Cancers. 13, 5, p. 1-14 14 p., 1106.Research output: Contribution to journal › Review article › peer-review
Open Access